
Axel Seher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8219828/publications.pdf Version: 2024-02-01



AVEL SEHED

#	Article	IF	CITATIONS
1	Low Energy Status under Methionine Restriction Is Essentially Independent of Proliferation or Cell Contact Inhibition. Cells, 2022, 11, 551.	4.1	1
2	Metabolic Fingerprinting of Murine L929 Fibroblasts as a Cell-Based Tumour Suppressor Model System for Methionine Restriction. International Journal of Molecular Sciences, 2021, 22, 3039.	4.1	2
3	Cysteine Restriction in Murine L929 Fibroblasts as an Alternative Strategy to Methionine Restriction in Cancer Therapy. International Journal of Molecular Sciences, 2021, 22, 11630.	4.1	2
4	HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings. International Journal of Molecular Sciences, 2020, 21, 8770.	4.1	6
5	Sensitization of head and neck squamous cell carcinoma to apoptosis by combinational SMAC mimetic and Fas ligand-Fc treatment inÂvitro. Journal of Cranio-Maxillo-Facial Surgery, 2020, 48, 685-693.	1.7	2
6	The Influence of Met Receptor Level on HGF-Induced Glycolytic Reprogramming in Head and Neck Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2020, 21, 471.	4.1	18
7	Targeting inhibitors of apoptosis in oral squamous cell carcinoma inÂvitro. Journal of Cranio-Maxillo-Facial Surgery, 2019, 47, 1589-1599.	1.7	8
8	The Selection of NFκB Inhibitors to Block Inflammation and Induce Sensitisation to FasL-Induced Apoptosis in HNSCC Cell Lines Is Critical for Their Use as a Prospective Cancer Therapy. International Journal of Molecular Sciences, 2019, 20, 1306.	4.1	12
9	Apoptosis-sensitizing activity of birinapant in head and neck squamous cell carcinoma cell lines. Oncology Letters, 2018, 15, 4010-4016.	1.8	9
10	Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro. Oncology Reports, 2017, 38, 1877-1885.	2.6	25
11	The anti-myeloma activity of bone morphogenetic protein 2 predominantly relies on the induction of growth arrest and is apoptosis-independent. PLoS ONE, 2017, 12, e0185720.	2.5	5
12	Co-treatment of wild-type EGFR head and neck cancer cell lines with afatinib and cisplatin. Molecular Medicine Reports, 2016, 13, 2338-2344.	2.4	14
13	Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion. Journal of Experimental Medicine, 2016, 213, 1881-1900.	8.5	143
14	Cytotoxic effects of SMAC-mimetic compound LCL161 in head and neck cancer cell lines. Clinical Oral Investigations, 2016, 20, 2325-2332.	3.0	17
15	Erlotinib and gefitinib responsiveness in head and neck cancer cell lines—a comparing analysis with cetuximab. Clinical Oral Investigations, 2016, 20, 759-769.	3.0	7
16	Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD. Blood, 2015, 126, 437-444.	1.4	29
17	<scp>MLN</scp> 4924 sensitizes monocytes and maturing dendritic cells for <scp>TNF</scp> â€dependent and â€independent necroptosis. British Journal of Pharmacology, 2015, 172, 1222-1236.	5.4	24
18	Soluble and Transmembrane TNF-Like Weak Inducer of Apoptosis Differentially Activate the Classical and Noncanonical NF-κB Pathway. Journal of Immunology, 2010, 185, 1593-1605.	0.8	83

Axel Seher

#	ARTICLE	IF	CITATIONS
19	Receptor oligomerization and beyond: a case study in bone morphogenetic proteins. BMC Biology, 2009, 7, 59.	3.8	116
20	Type I receptor binding of bone morphogenetic protein 6 is dependent on Nâ€glycosylation of the ligand. FEBS Journal, 2008, 275, 172-183.	4.7	92
21	Structure Analysis of Bone Morphogenetic Protein-2 Type I Receptor Complexes Reveals a Mechanism of Receptor Inactivation in Juvenile Polyposis Syndrome. Journal of Biological Chemistry, 2008, 283, 5876-5887.	3.4	51
22	A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor. BMC Structural Biology, 2007, 7, 6.	2.3	129